<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part4">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>4</PartID>
        <PartNumber>Part III</PartNumber>
        <PartSequenceNumber>4</PartSequenceNumber>
        <PartTitle>Angiogenesis</PartTitle>
        <PartChapterCount>5</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap20" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>20</ChapterID>
          <ChapterNumber>Chapter 20</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_20</ChapterDOI>
          <ChapterSequenceNumber>20</ChapterSequenceNumber>
          <ChapterTitle Language="En">Investigational Angiogenesis Inhibitors</ChapterTitle>
          <ChapterFirstPage>225</ChapterFirstPage>
          <ChapterLastPage>232</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>4</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_20" CorrespondingAffiliationID="Aff1_20">
              <AuthorName DisplayOrder="Western">
                <GivenName>Jeanny</GivenName>
                <GivenName>B.</GivenName>
                <FamilyName>Aragon-Ching</FamilyName>
              </AuthorName>
              <Contact>
                <Email>jaragonching@mfa.gwu.edu</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>William</GivenName>
                <FamilyName>Dahut</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_20">
              <OrgDivision>Department of Medicine</OrgDivision>
              <OrgName>George Washington University</OrgName>
              <OrgAddress>
                <City>Washington</City>
                <State>DC</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_20" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Targeting angiogenesis is an evolving field of cancer research. Tumor angiogenesis is considered as an important step in the progression and metastasis of prostate cancer. Several pathways that converge toward promotion of growth, proliferation, and survival of prostate cancer cells have been targeted, including modulation of proangiogenic factors such as vascular endothelial growth factor (VEGF), tyrosine kinases, cytokines, and the extracellular matrix. Accurately measuring antitumor activity remains a challenge with the use of investigational angiogenesis inhibitors in prostate cancer.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Antiangiogenesis</Keyword>
            <Keyword>Clinical trials</Keyword>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Tyrosine kinases</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Angiogenesis has rapidly emerged as a target for anticancer therapy in the last decade. Since the discovery by Dr. Judah Folkman that tumors require blood supply in order to proliferate [<CitationRef CitationID="CR1_20">1</CitationRef>], the strategy of inhibiting angiogenesis has become one of the most promising fields in cancer research. Almost all neoplasms exhibit neovascularization properties either within the tumor itself or its surrounding stroma by altering homeostatic mechanisms [<CitationRef CitationID="CR2_20">2</CitationRef>]. Tumor neovascularization is a multistep process that involves a complex interaction between proangiogenic stimuli, basement membrane disruption, endothelial cell migration to the extracellular matrix, endothelial cell proliferation, reorganization, and organization into new blood vessels [<CitationRef CitationID="CR3_20">3</CitationRef>]. Targeting angiogenesis involves blocking several different pathways in the angiogenesis cascade. This occurs either directly by targeting endothelial cells or indirectly by decreasing or blocking proangiogenic factors or its endothelial cell receptors, and may vary also by the ability to block one, two, or several factors [<CitationRef CitationID="CR4_20">4</CitationRef>]. At the forefront of investigational angiogenesis inhibitors is the lead agent bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF). Bevacizumab in combination with chemotherapy is approved by the Food and Drug Administration (FDA) for the treatment of metastatic colon, lung, and breast cancer [<CitationRef CitationID="CR5_20">5</CitationRef>]. Although limited activity has been shown using single agent bevacizumab [<CitationRef CitationID="CR6_20">6</CitationRef>, <CitationRef CitationID="CR7_20">7</CitationRef>], increased activity is seen when combined with chemotherapy [<CitationRef CitationID="CR8_20">8</CitationRef>–<CitationRef CitationID="CR10_20">10</CitationRef>], possibly due to normalization of the tumor vasculature [<CitationRef CitationID="CR11_20">11</CitationRef>], allowing for better delivery of chemotherapeutic drugs. Metastatic prostate cancer has also been shown to exhibit increased angiogenic activity [<CitationRef CitationID="CR12_20">12</CitationRef>]. As such, there is significant interest in targeting angiogenesis in prostate cancer.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Evidence for the Role of Angiogenesis in Prostate Cancer</Heading>
            <Para TextBreak="No">Tumor angiogenesis is a highly complex process with distinct yet overlapping mechanisms. Early studies showed that aberrant blood formation as well as increasing microvessel density (MVD) count, which was a measure of angiogenesis, were associated with recurrence or metastasis in malignancies including melanoma [<CitationRef CitationID="CR13_20">13</CitationRef>, <CitationRef CitationID="CR14_20">14</CitationRef>], breast [<CitationRef CitationID="CR15_20">15</CitationRef>, <CitationRef CitationID="CR16_20">16</CitationRef>], lung [<CitationRef CitationID="CR17_20">17</CitationRef>], and bladder cancer [<CitationRef CitationID="CR18_20">18</CitationRef>]. Elevated circulating VEGF and other soluble growth factors have been associated with poorer prognosis in prostate cancer [<CitationRef CitationID="CR19_20">19</CitationRef>, <CitationRef CitationID="CR20_20">20</CitationRef>]. Numerous studies have looked at the role of angiogenesis in prostate cancer and attempted to correlate the extent of angiogenesis with the risk for progression. One study examined the microvessel density using immunoperoxidase technique of staining endothelial cells for Factor VIII-related antigen [<CitationRef CitationID="CR12_20">12</CitationRef>] in radical prostatectomy specimens of 74 patients with invasive prostate cancers, of whom 29 eventually developed metastasis. Patients with metastatic disease had a higher mean MVD compared to those without metastasis. In another study using immunostaining against the von Willebrand factor to stain endothelial cells, 64 consecutive radical prostatectomy specimens were quantified for mean and maximal MVD [<CitationRef CitationID="CR21_20">21</CitationRef>]. Maximal MVD was found to be an important independent prognostic variable for survival in men with prostate cancer. Several other studies have reported the utility of microvessel density as a predictor of disease specific survival in prostate cancer, either alone [<CitationRef CitationID="CR22_20">22</CitationRef>, <CitationRef CitationID="CR23_20">23</CitationRef>] or in combination with standard prognostic factors for prediction of extraprostatic disease extension [<CitationRef CitationID="CR24_20">24</CitationRef>].</Para>
            <Para TextBreak="No">Prostate cancer cells also express and/or are regulated by a variety of cytokines or proteins that are involved in angiogenesis, basement membrane degradation, VEGF interaction, or endothelial cell activation [<CitationRef CitationID="CR25_20">25</CitationRef>]. For instance, VEGF mRNA and protein were found to be overexpressed in the highly metastatic LNCaP prostate cancer cell line variant LNCaP-LN3 compared to the less metastatic potential variant LNCaP-Pro5 [<CitationRef CitationID="CR26_20">26</CitationRef>]. Although basic fibroblast growth factor (bFGF) was not found to be overexpressed in this study, other in vitro studies have found augmented response to bFGF either alone or in addition to VEGF [<CitationRef CitationID="CR27_20">27</CitationRef>, <CitationRef CitationID="CR28_20">28</CitationRef>]. Other factors found to be upregulated in prostate cancer include the hypoxia-inducible factor-1 (HIF-1) [<CitationRef CitationID="CR29_20">29</CitationRef>–<CitationRef CitationID="CR32_20">32</CitationRef>], cyclooxygenase-2 (COX-2) [<CitationRef CitationID="CR33_20">33</CitationRef>], urokinase-type plasminogen activator [<CitationRef CitationID="CR34_20">34</CitationRef>, <CitationRef CitationID="CR35_20">35</CitationRef>], matrix metalloproteinases [<CitationRef CitationID="CR36_20">36</CitationRef>–<CitationRef CitationID="CR38_20">38</CitationRef>], and cytokines such as interleukin-8 [<CitationRef CitationID="CR39_20">39</CitationRef>] and tumor necrosis factor (TNF) [<CitationRef CitationID="CR40_20">40</CitationRef>, <CitationRef CitationID="CR41_20">41</CitationRef>]. Several other dysregulated pathways that are involved in the angiogenic signaling cascade have been described, including the Ras/Raf/Mek/Erk pathway [<CitationRef CitationID="CR42_20">42</CitationRef>–<CitationRef CitationID="CR44_20">44</CitationRef>] and phosphatidylinositol-3 kinase/protein kinase B (PI3/AKT) [<CitationRef CitationID="CR31_20">31</CitationRef>, <CitationRef CitationID="CR45_20">45</CitationRef>] signaling pathway via inactivation of phosphatase and tensin homologue (PTEN) [<CitationRef CitationID="CR46_20">46</CitationRef>], all contributing toward tumor angiogenesis and proliferation.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Investigational Angiogenesis Inhibitors</Heading>
            <Para TextBreak="No">The emergence of different pathways and molecular targets for angiogenesis inhibition has resulted in a robust field of research investigation in prostate cancer (see Table <InternalRef RefID="Tab1">20.1</InternalRef>). This section describes the clinical trials investigating agents that inhibit various targets, including the VEGF ligands and its receptors, receptor tyrosine kinases involved in angiogenic signaling, and the epithelial-stromal interactions including proteinases and cytokines that support the surrounding microenvironment.<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 20.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Selected antiangiogenic agents in clinical development for prostate cancer</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="4">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Mechanisms and drugs</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Cellular targets</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Clinical phase of development</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>References</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry nameend="c4" namest="c1">
                        <SimplePara>
                          <Emphasis Type="Italic">Anti-VEGF agents</Emphasis>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1" morerows="1">
                        <SimplePara>Bevacizumab</SimplePara>
                      </entry>
                      <entry colname="c2" morerows="1">
                        <SimplePara>VEGF-A</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Phase II in combination with docetaxel and thalidomide</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR57_20">57</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c3">
                        <SimplePara>Phase III in combination with docetaxel and estramustine</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR54_20">54</CitationRef>, <CitationRef CitationID="CR55_20">55</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1" morerows="1">
                        <SimplePara>VEGF Trap</SimplePara>
                      </entry>
                      <entry colname="c2" morerows="1">
                        <SimplePara>VEGF, PlGF</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Phase I in combination with docetaxel</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR61_20">61</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c3">
                        <SimplePara>Phase III in combination with docetaxel</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR62_20">62</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry nameend="c4" namest="c1">
                        <SimplePara>
                          <Emphasis Type="Italic">Small-molecule tyrosine kinase inhibitors</Emphasis>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1" morerows="1">
                        <SimplePara>AZD2171</SimplePara>
                      </entry>
                      <entry colname="c2" morerows="1">
                        <SimplePara>VEGFR1, VEGFR2, VEGFR-3, PDGFR, c-Kit</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Phase I single agent</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR76_20">76</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c3">
                        <SimplePara>Phase II single agent</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR77_20">77</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1" morerows="1">
                        <SimplePara>Sorafenib</SimplePara>
                      </entry>
                      <entry colname="c2" morerows="1">
                        <SimplePara>VEGFR, PDGFR, c-Kit, Raf kinase</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Phase II single agent</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR68_20">68</CitationRef>–<CitationRef CitationID="CR70_20">70</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c3">
                        <SimplePara>Phase II in combination with docetaxel</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR71_20">71</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Tandutinib (MLN518/CT53518)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>FLT3, PDGFR, c-Kit</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Phase II single agent</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR78_20">78</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry nameend="c4" namest="c1">
                        <SimplePara>
                          <Emphasis Type="Italic">Agents that target extracellular matrix, cytokines, or cell-matrix adhesion</Emphasis>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Thalidomide</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Unknown, immunomodulatory</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Phase II in combination with docetaxel and bevacizumab</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR57_20">57</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Cilengitide (EMD-121974)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Alpha-5 beta-3 integrin</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Phase II single agent</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>[<CitationRef CitationID="CR90_20">90</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Emphasis Type="Italic">FLT3</Emphasis> FMS-like tyrosine kinase 3; <Emphasis Type="Italic">PDGFR</Emphasis> platelet-derived growth factor receptor; <Emphasis Type="Italic">PlGF</Emphasis> platelet growth factor; <Emphasis Type="Italic">VEGF</Emphasis> vascular endothelial growth factor</SimplePara>
                </tfooter>
              </Table>
            </Para>
            <Section2 ID="Sec4">
              <Heading>
                <Emphasis>Targeting VEGF and VEGF-Receptor (VEGF-R) Family</Emphasis>
              </Heading>
              <Para TextBreak="No">The VEGF family of ligands and receptors constitute a diverse yet distinct pathway of activating signals that result ultimately in proliferation, endothelial cell migration, and survival of newly formed vasculature [<CitationRef CitationID="CR47_20">47</CitationRef>, <CitationRef CitationID="CR48_20">48</CitationRef>]. At least seven members of this family have been described [<CitationRef CitationID="CR49_20">49</CitationRef>–<CitationRef CitationID="CR51_20">51</CitationRef>]. VEGF-A isoform is the most widely studied mediator of tumor angiogenesis [<CitationRef CitationID="CR52_20">52</CitationRef>] and binds to major VEGF receptors 1 and 2 (VEGFR1 and VEGFR2), leading to receptor dimerization and a cascade of signaling pathways. The lead angiogenesis inhibitor bevacizumab was a humanized IgG monoclonal antibody against all isoforms of VEGF-A [<CitationRef CitationID="CR53_20">53</CitationRef>]. An early clinical trial using single-agent bevacizumab in prostate cancer used a dose of 10 mg/kg every 2 weeks for six infusions. Results showed no objective or partial responses by day 70 in the eight patients who had measurable disease and no significant PSA declines, although there were PSA declines of &lt;50% in 4 of 15 patients [<CitationRef CitationID="CR7_20">7</CitationRef>]. Although single-agent bevacizumab lacked significant activity in prostate cancer, the encouraging results from other clinical trials using combined bevacizumab and chemotherapy led to a Cancer and Leukemia Group B (CALGB) trial 90006 that combined bevacizumab with docetaxel and estramustine [<CitationRef CitationID="CR54_20">54</CitationRef>]. The CALGB 90006 trial enrolled 79 patients, and a 77% PSA response rate was observed (defined as PSA decline of &gt;50% in 58 of 75 patients with sufficient PSA data) [<CitationRef CitationID="CR55_20">55</CitationRef>]. Forty-four percent (15 out of 34 patients who had measurable disease) achieved a partial response (PR), and 32% achieved stable disease (SD) for at least 6 weeks. In another study, the CALGB 90401 trial had the primary objective of comparing overall survival between men with chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC) treated with docetaxel and prednisone and those treated with docetaxel, prednisone, and bevacizumab [<CitationRef CitationID="CR56_20">56</CitationRef>]. Preliminary results demonstrate that despite an improvement in PFS, measurable disease response and post-therapy PSA decline, the addition of bevacizumab to docetaxel and prednisone did not improve OS in men with mCRPC, and was associated with greater morbidity and mortality. A trial at the National Cancer Institute (NCI) utilized a combination of bevacizumab given at 15 mg/kg every 3 weeks, which constituted one cycle, in combination with docetaxel 75 mg/m<Superscript>2</Superscript> every 3 weeks, thalidomide 200 mg daily, prednisone 10 mg daily, with appropriate thromboprophylaxis. This phase II trial accrued 60 patients with metastatic CRPC, with a median of 66 years (range 44–79), median Gleason score of 8, on-study PSA of 99 ng/mL (range: 6.0–4,399), and prestudy PSA doubling time of 1.6 months (0.3–18.2, 81% &lt;3 months) [<CitationRef CitationID="CR57_20">57</CitationRef>]. Ninety percent of patients receiving the combination therapy had PSA declines of ≥ 50%, with a median time to progression of 18.3 months and a median OS of 28.2 months. The four drug regimen was generally tolerable with manageable toxicities [57]. Thus, despite the negative findings in the CALGB 90401 study, there still may be a role for antiangiogenic agents in advanced prostate cancer. Future studies are needed to address treatment combinations and to clarify the role of angiogenesis as a target in mCRPC (see <ExternalRef>
                  <RefSource>Chap. 18</RefSource>
                  <RefTarget Address="10.1007/978-1-60327-829-4_19" TargetType="DOI"/>
                </ExternalRef>, Bevacizumab in Advanced Prostate Cancer).</Para>
              <Para TextBreak="No">Another strategy for targeting VEGF is through blocking the VEGF receptors. One of the most potent VEGF-R inhibitors is a decoy receptor fusion protein, which comprises the extracellular domains of VEGFR1 and VEGFR2, fused to the constant region (Fc portion) of human IgG1 [<CitationRef CitationID="CR58_20">58</CitationRef>]. Earlier studies using truncated soluble VEGFR1 inhibitors, while effective at inhibiting VEGF bioactivity and angiogenesis, also exhibited poor pharmacokinetic profile and had to be administered more frequently and at high concentrations [<CitationRef CitationID="CR59_20">59</CitationRef>, <CitationRef CitationID="CR60_20">60</CitationRef>]. Engineering of the parental VEGF Trap (aflibercept) by switching the Ig domains resulted in a fusion protein that interacts minimally with the extracellular matrix, thus improving its pharmacokinetic profile while maintaining in vivo tumor growth suppression [<CitationRef CitationID="CR58_20">58</CitationRef>]. A phase I dose escalation study using aflibercept in combination with docetaxel 75 mg/m<Superscript>2</Superscript> every 3 weeks has been preliminarily reported [<CitationRef CitationID="CR61_20">61</CitationRef>]. The recommended dosing of aflibercept at 6 mg/kg with docetaxel did not show any exacerbation of docetaxel-related side effects. In prostate cancer, a phase III trial using aflibercept with docetaxel and prednisone is currently ongoing, with the primary objective of determining improvement in overall survival for metastatic CRPC [<CitationRef CitationID="CR62_20">62</CitationRef>].</Para>
              <Para TextBreak="No">While these agents targeting VEGF are very promising, patterns of resistance against antiangiogenic agents given in combination with chemotherapy, are slowly emerging [<CitationRef CitationID="CR52_20">52</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>Targeting Receptor Tyrosine Kinases Involved in Angiogenesis</Heading>
              <Para TextBreak="No">Tyrosine kinases are key enzymes that play a major role in regulating various cellular processes that modulate signaling for tumor growth, proliferation, and survival [<CitationRef CitationID="CR63_20">63</CitationRef>]. Binding of VEGF to VEGFR2 triggers intracellular signaling cascade via autophosphorylation and activation of the tyrosine kinase domains [<CitationRef CitationID="CR64_20">64</CitationRef>, <CitationRef CitationID="CR65_20">65</CitationRef>], thus promoting and sustaining angiogenesis. As such, small-molecule inhibitors that target these receptor tyrosine kinases have been investigated in prostate cancer.</Para>
              <Para TextBreak="No">Sorafenib is a multikinase inhibitor that targets Raf kinase and the tyrosine kinases including VEGF-R, platelet derived growth factor receptor (PDGF-R), stem cell factor receptor c-kit, and c-Ret [<CitationRef CitationID="CR66_20">66</CitationRef>]. Preclinical tumor models have shown apoptosis in response to sorafenib inhibition [<CitationRef CitationID="CR67_20">67</CitationRef>]. Dysregulation of the Ras/Raf/Mitogen activated protein (Map) kinase was also associated with prostate cancer progression [<CitationRef CitationID="CR43_20">43</CitationRef>, <CitationRef CitationID="CR44_20">44</CitationRef>], providing the rationale for the use of sorafenib in prostate cancer. There have been several studies utilizing sorafenib for metastatic CRPC [<CitationRef CitationID="CR68_20">68</CitationRef>–<CitationRef CitationID="CR70_20">70</CitationRef>]. Modest response has been observed using this agent, with apparent lack of reliability in using PSA as a measure of response. One trial enrolled an initial 22 out of 46 patients [<CitationRef CitationID="CR68_20">68</CitationRef>]. No PSA declines &gt;50% were noted. However, discordance between increasing PSA values and improvement in bone lesions by bone scan was observed in two patients, and accrual to the full 46 patients continued. A search for alternative biomarkers using phosphorylated extracellular signal regulated kinase (Erk) also showed no consistent correlation with response. Another trial enrolled 57 patients with metastatic CRPC and had a primary end point of PFS of ≥12 weeks based on PSA progression [<CitationRef CitationID="CR70_20">70</CitationRef>]. Of the eight patients with measurable disease, four patients were categorized with SD. Of the 47 patients evaluable for PSA response, 11 patients achieved SD according to PSA-based criteria, with two additional patients who had PSA declines &gt; 50%. These trials also showed immediate posttreatment PSA declines without administration of any further therapy, suggesting possible modulation of PSA secretion by sorafenib [<CitationRef CitationID="CR68_20">68</CitationRef>]. Combinations using sorafenib and docetaxel are currently underway for metastatic CRPC patients [<CitationRef CitationID="CR71_20">71</CitationRef>].</Para>
              <Para TextBreak="No">Sunitinib is another small-molecule inhibitor targeting VEGFR1 and VEGFR2, along with PDGF-R, c-kit, and <Emphasis Type="Italic">RET</Emphasis> kinases [<CitationRef CitationID="CR72_20">72</CitationRef>]. It has exhibited antitumor properties in preclinical models, especially in combination with docetaxel [<CitationRef CitationID="CR73_20">73</CitationRef>]. As such, a phase 1 and 2 dose escalating trial using docetaxel and sunitinib in chemotherapy-naïve patients with metastatic CRPC is currently being investigated [<CitationRef CitationID="CR74_20">74</CitationRef>].</Para>
              <Para TextBreak="No">A promising, highly potent, ATP-competitive small-molecule that inhibits all VEGF receptors has also shown activity in prostate cancer. AZD2171 (cediranib) has been studied in patients with advanced solid malignancies with hypertension as the most frequently observed dose limiting toxicity (DLT) [<CitationRef CitationID="CR75_20">75</CitationRef>]. A phase I dose escalation study utilizing AZD2171 in patients with prostate cancer has been completed [<CitationRef CitationID="CR76_20">76</CitationRef>]. Similar to sorafenib, posttreatment PSA declines were noted in four patients within 30 days following drug discontinuation. There was also one objective response noted. A phase II clinical trial using AZD2171 as second line therapy for patients with metastatic CRPC who have failed prior docetaxel is currently ongoing at the NCI [<CitationRef CitationID="CR77_20">77</CitationRef>]. The primary endpoint was a 30% 6 month probability of progression-free survival using clinical and radiographic criteria. Of the 18 patients currently enrolled, significant decreases in lymph node as well as other sites of metastases, including the lung, liver, and bone lesions have been documented despite discordant effect on PSA levels. Of the 11 patients who had measurable disease, two patients had PR. Correlative dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) showed circulatory and vascular changes which correlated with clinical response to AZD2171 in some patients.</Para>
              <Para TextBreak="No">Tandutinib is another small-molecule compound that inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT, and PDGF receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Tandutinib has also been reported to have activity in metastatic CRPC patients who have progressed on taxanes [<CitationRef CitationID="CR78_20">78</CitationRef>]. This phase II trial used oral tandutinib at 500 mg twice daily dosage given every 28 days with the primary endpoint of measuring freedom from disease progression in 8 weeks. Two (13%) out of 15 evaluable patients were free from symptomatic or radiological progression beyond 8 weeks (35, 50 weeks), and PSA declines of 50% and 40%, respectively were seen in these two patients. Unlike sorafenib and AZD2171, no PSA declines were noted following drug discontinuation.</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Targeting the Extracellular Matrix, Cytokines, and Cell–Matrix Adhesion</Heading>
              <Para TextBreak="No">It is increasingly being recognized that different cytokines such as FGF, transforming growth factor (TGF), endothelial cell-activating factors, stromal fibroblasts, and components of the tumor microenvironment, all help to sustain angiogenesis [<CitationRef CitationID="CR79_20">79</CitationRef>, <CitationRef CitationID="CR80_20">80</CitationRef>]. To this end, thalidomide and its analogues have been widely studied for its antiangiogenic and immunomodulatory effects in prostate cancer [<CitationRef CitationID="CR81_20">81</CitationRef>–<CitationRef CitationID="CR83_20">83</CitationRef>], with encouraging results (see <ExternalRef>
                  <RefSource>Chap. 19</RefSource>
                  <RefTarget Address="10.1007/978-1-60327-829-4_19" TargetType="DOI"/>
                </ExternalRef>, Thalidomide and Analogs). The thalidomide analogue lenalidomide has also been studied in solid tumors [<CitationRef CitationID="CR84_20">84</CitationRef>], and in combination with docetaxel in prostate cancer [<CitationRef CitationID="CR85_20">85</CitationRef>]. This open-label phase I trial utilized docetaxel at two dose levels every 3 weeks at 60 mg/m<Superscript>2</Superscript> and 75 mg/m<Superscript>2</Superscript>, prednisone 5 mg twice a day, and lenalidomide at doses of 10 mg, 15 mg, 20 mg, or 25 mg. Of the 13 patients with measurable disease, five patients achieved PR (38.5%) and seven patients (53.9%) had SD. Another phase I trial combining lenalidomide with docetaxel [<CitationRef CitationID="CR86_20">86</CitationRef>] in patients with solid tumors showed that of the nine patients with prostate cancer, SD was seen in five patients and PSA declines of 32–95% were observed.</Para>
              <Para TextBreak="No">5,6-Dimethylxanthenone acetic acid (DMXAA) is an agent that disrupts the tumor vasculature by directly causing apoptosis and necrosis as well as tumor necrosis factor (TNF) induction [<CitationRef CitationID="CR87_20">87</CitationRef>]. A randomized phase II trial in metastatic prostate cancer utilizing docetaxel 75 mg/m<Superscript>2</Superscript> every 3 weeks, with or without DMXAA at 1,200 mg/m<Superscript>2</Superscript> every 21 days has been completed. Sixty-two and a half percent of patients in the DMXAA treatment arm had at least a 30% reduction in PSA during the first 3 months, compared with 47.4% patients in the control arm, who received docetaxel alone [<CitationRef CitationID="CR88_20">88</CitationRef>], with tolerable safety profiles.</Para>
              <Para TextBreak="No">An integral component in the maintenance of the basal membrane is the integrins, which are heterodimer transmembrane receptors composed of an alpha and beta subunit in the extracellular matrix, of which the heterodimers α(alpha)Vβ(beta)3 and α(alpha)Vβ(beta)5 were the earliest known integrin targets for inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and tumor angiogenesis [<CitationRef CitationID="CR89_20">89</CitationRef>]. Integrins recognize several ligands via their arginine-glycine-aspartic acid (RGD) sequence, including, but not limited to, laminin, fibrinogen, fibronectin, thrombospondin, matrix metalloproteinase-2 (MMP-2), and FGF-2. Several approaches in blocking integrins are in development, including monoclonal antibodies against integrins and synthetic peptides or peptidomimetics that contain the RGD sequence. One of the synthetic peptides in development which has been studied in a phase II clinical trial for chemotherapy-naïve asymptomatic metastatic CRPC patients is cilengitide (EMD 121974) [<CitationRef CitationID="CR90_20">90</CitationRef>]. The primary endpoint was a 6-month objective progression-free rate, excluding PSA as a criterion. Using a Simon two-stage design, patients were randomized to cilengitide 500 mg or 2,000 mg intravenously twice a week in 6-week cycles. SD was documented as the best objective response in 27% of patients on the 500 mg arm and 36% on 2,000 mg arm. No significant trends in biologic markers such as <Emphasis Type="Italic">N</Emphasis>-telopeptides were noted. Based on this activity, accrual to the second stage was halted.</Para>
              <Para TextBreak="No">The potential role of MMPs in prostate cancer progression has also been investigated [<CitationRef CitationID="CR91_20">91</CitationRef>]. Several agents that modulate angiogenesis partly via MMP inhibition include endostatin [<CitationRef CitationID="CR92_20">92</CitationRef>], TNP-470 [<CitationRef CitationID="CR93_20">93</CitationRef>], and perhaps 2-methoxyestradiol [<CitationRef CitationID="CR94_20">94</CitationRef>]. Although these agents have been studied in prostate cancer, significant meaningful clinical responses have not been seen.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec7" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">Targeting angiogenesis is a burgeoning field of cancer research. Early investigations have established the improved utility of combining these targeted agents with cytotoxic chemotherapy without undue additional toxicity. Specific challenges include defining outcome measures, especially since PSA is proving to be an unreliable surrogate marker for response or progression. The search for appropriate biomarkers as surrogates for response is ongoing and must be clinically validated, including circulating levels of proangiogenic factors, circulating tumor cells or endothelial cells, and assessment of functional imaging, such as DCE-MRI. In addition, patterns of resistance against these antiangiogenic agents, are slowly emerging [<CitationRef CitationID="CR52_20">52</CitationRef>]. It had been an initially held belief that endothelial cells were genetically stable and thus might not develop resistance. However, some harbor cytogenetic abnormalities would render them with acquired resistance [<CitationRef CitationID="CR95_20">95</CitationRef>]. Increasing recognition of varying mechanisms of resistance would be valuable in developing strategies for circumventing this resistance patterns. One possible approach is to use combinational therapies, whether with additional cytotoxic chemotherapy or another antiangiogenic agent that utilizes a different activating pathway. The optimal dosing schedule as well as potential long-term safety antiangiogenic agents alone or in combination must also be addressed.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_20.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_20">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Tumor angiogenesis: therapeutic implications</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>285</VolumeID>
                <FirstPage>1182</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>4938153</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM197108122850711</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE38%2FgvVCqsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_20">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IJ</Initials>
                  <FamilyName>Fidler</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Modulation of the organ microenvironment for treatment of cancer metastasis</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>87</VolumeID>
                <FirstPage>1588</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>7563201</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/87.21.1588</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK28%2Fis1altw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995;87:1588–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_20">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Watson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Ingber</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">Induction of angiogenesis during the transition from hyperplasia to neoplasia</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>339</VolumeID>
                <FirstPage>58</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>2469964</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/339058a0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1M3jvVGntg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_20">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Angiogenesis: an organizing principle for drug discovery?</ArticleTitle>
                <JournalTitle>Nat Rev Drug Discov</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>273</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>17396134</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrd2115</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjs1SisL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_20">
              <CitationNumber>5</CitationNumber>
              <BibUnstructured>FDA Approval for Bevacizumab-National Cancer Institute. (Accessed May 20, 2008, at <ExternalRef>
                  <RefSource>http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab</RefSource>
                  <RefTarget Address="http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab" TargetType="URL"/>
                </ExternalRef>)</BibUnstructured>
            </Citation>
            <Citation ID="CR6_20">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Cohen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gootenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Keegan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer</ArticleTitle>
                <JournalTitle>Oncologist</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>356</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>17405901</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1634/theoncologist.12-3-356</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlsVSqur8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12:356–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_20">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Reese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Fratesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Corry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>65</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1525-1411.2001.32007.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reese DM, Fratesi P, Corry M, et al. A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate 2001;3:65–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_20">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Hurwitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Fehrenbacher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Novotny</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>350</VolumeID>
                <FirstPage>2335</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>15175435</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa032691</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXks1Gjt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_20">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Hurwitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Fehrenbacher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Hainsworth</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>3502</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>15908660</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.10.017</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlsVyhsrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_20">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sandler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Gray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Perry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>355</VolumeID>
                <FirstPage>2542</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>17167137</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa061884</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtlWqsbzI</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_20">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Jain</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>307</VolumeID>
                <FirstPage>58</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>15637262</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1104819</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXnvFar</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jain, RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_20">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Carroll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Flax</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>143</VolumeID>
                <FirstPage>401</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7688183</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3szktlWqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_20">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Srivastava</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Laidler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LE</Initials>
                  <FamilyName>Hughes</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1986</Year>
                <ArticleTitle Language="En">Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study</ArticleTitle>
                <JournalTitle>Eur J Cancer Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>1205</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>2434333</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0277-5379(86)90322-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2s7jtlOksA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Srivastava A, Laidler P, Hughes LE, et al. Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study. Eur J Cancer Clin Oncol 1986;22:1205–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_20">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Srivastava</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Laidler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RP</Initials>
                  <FamilyName>Davies</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1988</Year>
                <ArticleTitle Language="En">The prognostic significance of tumor vascularity in intermediate-thickness (0.76–4.0 mm thick) skin melanoma. A quantitative histologic study</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>133</VolumeID>
                <FirstPage>419</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>3189515</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1M%2FkslOgtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Srivastava A, Laidler P, Davies RP, et al. The prognostic significance of tumor vascularity in intermediate-thickness (0.76–4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol 1988;133:419–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_20">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Pozza</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>84</VolumeID>
                <FirstPage>1875</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>1281237</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/84.24.1875</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s%2FpsFWhtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_20">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Semple</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Welch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>324</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>1701519</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199101033240101</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M%2FnsVWquw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Semple JP, Welch WR, Folkman, J. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_20">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Macchiarini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Fontanini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Hardin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Relation of neovascularisation to metastasis of non-small-cell lung cancer</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>340</VolumeID>
                <FirstPage>145</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>1378165</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0140-6736(92)93217-B</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK38zis1CltA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340:145–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_20">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Jaeger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Chew</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>154</VolumeID>
                <FirstPage>69</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>7539869</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)67230-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M3psFWjsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154:69–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_20">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Borre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Nerstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Overgaard</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>1882</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>10815911</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3cvhtVOgug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000;6:1882–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_20">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SF</Initials>
                  <FamilyName>Shariat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VA</Initials>
                  <FamilyName>Anwuri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Lamb</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>1655</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>15117988</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.09.142</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWlsro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shariat SF, Anwuri VA, Lamb DJ, et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004;22:1655–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_20">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BV</Initials>
                  <FamilyName>Offersen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Borre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Overgaard</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">(1998) Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer</ArticleTitle>
                <JournalTitle>APMIS</JournalTitle>
                <VolumeID>106</VolumeID>
                <FirstPage>463</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9637268</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1699-0463.1998.tb01372.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1c3pvFegug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Offersen BV, Borre M, Overgaard, J. (1998) Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. APMIS 1998;106:463–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_20">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Borre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BV</Initials>
                  <FamilyName>Offersen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Nerstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Overgaard</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>78</VolumeID>
                <FirstPage>940</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>9764587</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/bjc.1998.605</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1cvjsFKitA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_20">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Borre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Bentzen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Nerstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Overgaard</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Tumor cell proliferation and survival in patients with prostate cancer followed expectantly</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>159</VolumeID>
                <FirstPage>1609</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>9554364</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00005392-199805000-00054</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1c3htlShtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Borre M, Bentzen SM, Nerstrom B, Overgaard J. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 1998;159:1609–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_20">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Bostwick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Wheeler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Blute</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>48</VolumeID>
                <FirstPage>47</FirstPage>
                <LastPage>57</LastPage>
                <Occurrence Type="PID">
                  <Handle>8693651</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(96)00149-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK28zgsFyhsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bostwick DG, Wheeler TM, Blute M, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996;48:47–57.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_20">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Nicholson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Theodorescu</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Angiogenesis and prostate cancer tumor growth</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>125</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>14689586</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/jcb.10772</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlvV2gug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 2004;91:125–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_20">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Balbay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Pettaway</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kuniyasu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>783</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10213213</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXislOnsLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Balbay MD, Pettaway CA, Kuniyasu H, et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 1999;5:783–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_20">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Gaudric</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>N’Guyen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Moenner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Quantification of angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model</ArticleTitle>
                <JournalTitle>Ophthalmic Res</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>181</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>1407961</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1159/000267166</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s%2Fis1WlsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gaudric A, N’Guyen T, Moenner M, et al. Quantification of angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model. Ophthalmic Res 1992;24:181–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_20">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Pepper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ferrara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Orci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Montesano</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>189</VolumeID>
                <FirstPage>824</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>1281999</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0006-291X(92)92277-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXnsVejug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_20">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Agani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Baccala</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>5280</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>9850048</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXotVSksbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhong H, Agani F, Baccala AA, et al. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res 1998;58:5280–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_20">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>DeMarzo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Laughner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>5830</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>10582706</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXnslygsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhong H, DeMarzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_20">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Chiles</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldser</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>1541</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>10749120</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXit1aqt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_20">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Kimbro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Simons</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Hypoxia-inducible factor-1 in human breast and prostate cancer</ArticleTitle>
                <JournalTitle>Endocr Relat Cancer</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>739</FirstPage>
                <LastPage>49</LastPage>
                <Occurrence Type="PID">
                  <Handle>16954428</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/erc.1.00728</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtlequrzN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006;13:739–49.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_20">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>XH</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kirschenbaum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yao</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line</ArticleTitle>
                <JournalTitle>Clin Exp Metastasis</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>687</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>10919714</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1023/A:1006728119549</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlslGit7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liu XH, Kirschenbaum A, Yao S, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999;17:687–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_20">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Hoosein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Boyd</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Hollas</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines</ArticleTitle>
                <JournalTitle>Cancer Commun</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>255</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>1653586</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38XksVKn</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hoosein NM, Boyd DD, Hollas WJ, et al. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 1991;3:255–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_20">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Hollas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Hoosein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LW</Initials>
                  <FamilyName>Chung</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Thromb Haemost</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>662</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>1337629</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXitFSgtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hollas W, Hoosein N, Chung LW, et al. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost 1992;68:662–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_20">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Nagakawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Murakami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Yamaura</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Cancer Lett</JournalTitle>
                <VolumeID>155</VolumeID>
                <FirstPage>173</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10822133</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0304-3835(00)00425-0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjsVGitr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nagakawa O, Murakami K, Yamaura T, et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000;155:173–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_20">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Trudel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Fradet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Meyer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry</ArticleTitle>
                <JournalTitle>Hum Pathol</JournalTitle>
                <VolumeID>39</VolumeID>
                <FirstPage>731</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18329693</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.humpath.2007.09.021</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlvVCnur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trudel D, Fradet Y, Meyer F, et al. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 2008;39:731–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_20">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Trudel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Fradet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Meyer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Significance of MMP-2 expression in prostate cancer: an immunohistochemical study</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>8511</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>14679018</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXpvVagurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trudel D, Fradet Y, Meyer F, et al. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 2003;63:8511–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_20">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Inoue</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Slaton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BY</Initials>
                  <FamilyName>Eve</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>2104</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>10815938</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXktVWit78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000;6:2104–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_20">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FA</Initials>
                  <FamilyName>Ferrer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RI</Initials>
                  <FamilyName>Andrawis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>157</VolumeID>
                <FirstPage>2329</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>9146665</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)64775-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmsVehsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_20">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FA</Initials>
                  <FamilyName>Ferrer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RI</Initials>
                  <FamilyName>Andrawis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>51</VolumeID>
                <FirstPage>161</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9457313</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(97)00491-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1c7hvVKguw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51:161–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_20">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Erlich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Tal-Or</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Liebling</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>72</VolumeID>
                <FirstPage>427</FirstPage>
                <LastPage>36</LastPage>
                <Occurrence Type="PID">
                  <Handle>16780807</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.bcp.2006.05.007</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntFWkur8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Erlich S, Tal-Or P, Liebling R, et al. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 2006;72:427–36.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_20">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gioeli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Mandell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Petroni</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Activation of mitogen-activated protein kinase associated with prostate cancer progression</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>279</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>9927031</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXntFKkuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gioeli D, Mandell JW, Petroni GR, et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_20">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gioeli</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Signal transduction in prostate cancer progression</ArticleTitle>
                <JournalTitle>Clin Sci (Lond)</JournalTitle>
                <VolumeID>108</VolumeID>
                <FirstPage>293</FirstPage>
                <LastPage>308</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1042/CS20040329</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXisV2jtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gioeli D. Signal transduction in prostate cancer progression. Clin Sci (Lond) 2005;108:293–308.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_20">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SN</Initials>
                  <FamilyName>Malik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Brattain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Ghosh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>1168</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>11948129</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_20">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Giri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ittmann</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma</ArticleTitle>
                <JournalTitle>Hum Pathol</JournalTitle>
                <VolumeID>30</VolumeID>
                <FirstPage>419</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>10208463</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0046-8177(99)90117-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3itlWlsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 1999;30:419–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_20">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Hicklin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Ellis</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>1011</FirstPage>
                <LastPage>27</LastPage>
                <Occurrence Type="PID">
                  <Handle>15585754</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.06.081</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXit1Gnsro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–27.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_20">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ferrara</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">VEGF and the quest for tumor angiogenesis factors</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>795</FirstPage>
                <LastPage>803</LastPage>
                <Occurrence Type="PID">
                  <Handle>12360282</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc909</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XnsVGrtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002;2:795–803.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_20">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Yamazaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Morita</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Molecular and functional diversity of vascular endothelial growth factors</ArticleTitle>
                <JournalTitle>Mol Divers</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>515</FirstPage>
                <LastPage>27</LastPage>
                <Occurrence Type="PID">
                  <Handle>16972015</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s11030-006-9027-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xht1Ohsb3J</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006;10:515–27.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_20">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic</ArticleTitle>
                <JournalTitle>Cancer Metastasis Rev</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>443</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>17786538</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s10555-007-9071-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1yktLnJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Epstein RJ. (2007) VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007;26:443–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_20">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Neufeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Cohen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Gengrinovitch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Poltorak</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Vascular endothelial growth factor (VEGF) and its receptors</ArticleTitle>
                <JournalTitle>FASEB J</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>9</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>9872925</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXlt1ygsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_20">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Kerbel</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Tumor angiogenesis</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>358</VolumeID>
                <FirstPage>2039</FirstPage>
                <LastPage>49</LastPage>
                <Occurrence Type="PID">
                  <Handle>18463380</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMra0706596</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlsFyrtro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039–49.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_20">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Presta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>O’Connor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>4593</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9377574</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmslKqtLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_20">
              <CitationNumber>54</CitationNumber>
              <BibUnstructured>Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006 [abstract]. Proc Am Soc Clin Oncol 2003;22:No. 1578.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_20">
              <CitationNumber>55</CitationNumber>
              <BibUnstructured>Picus J. Docetaxel/bevacizumab (Avastin) in prostate cancer [abstract]. Cancer Invest 2004;22:60:No. 46.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_20">
              <CitationNumber>56</CitationNumber>
              <BibUnstructured>Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. ASCO Annual Meeting Proceedings J Clin Oncol 2010;28:LBA4511.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_20">
              <CitationNumber>57</CitationNumber>
              <BibUnstructured>Ning YM, Gulley JL, Arlen PM, et al. A phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070–6. doi:<ExternalRef><RefSource>10.1200/JCO.2009.25.4524</RefSource><RefTarget Address="10.1200/JCO.2009.25.4524" TargetType="DOI"/></ExternalRef>.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_20">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Holash</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Davis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Papadopoulos</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">VEGF-Trap: a VEGF blocker with potent antitumor effects</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>11393</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12177445</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.172398299</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XmslSmu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_20">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ferrara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Davis-Smyth</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Vascular endothelial growth factor is essential for corpus luteum angiogenesis</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>336</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>9500609</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm0398-336</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhs1Kisbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_20">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HP</Initials>
                  <FamilyName>Gerber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TH</Initials>
                  <FamilyName>Vu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>623</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10371499</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/9467</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjs1Kmtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_20">
              <CitationNumber>61</CitationNumber>
              <BibUnstructured>Isambert N, Freyer G, Zanetta S, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results [abstract]. J Clin Oncol 2008:No. 3599.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_20">
              <CitationNumber>62</CitationNumber>
              <BibUnstructured>NCT00519285. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). (Accessed April 15, 2008 at <ExternalRef>
                  <RefSource>http://clinicaltrials.gov/ct2/show/NCT00519285</RefSource>
                  <RefTarget Address="http://clinicaltrials.gov/ct2/show/NCT00519285" TargetType="URL"/>
                </ExternalRef>)</BibUnstructured>
            </Citation>
            <Citation ID="CR63_20">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Arora</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Scholar</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Role of tyrosine kinase inhibitors in cancer therapy</ArticleTitle>
                <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                <VolumeID>315</VolumeID>
                <FirstPage>971</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16002463</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1124/jpet.105.084145</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtlalur3L</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_20">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EK</Initials>
                  <FamilyName>Bergsland</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Vascular endothelial growth factor as a therapeutic target in cancer</ArticleTitle>
                <JournalTitle>Am J Health Syst Pharm</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>S4</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>15552621</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVentrfF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bergsland EK. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm 2004;61:S4–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_20">
              <CitationNumber>65</CitationNumber>
              <BibUnstructured>Parikh AA, Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am 2004;18:951–71,vii. doi:<ExternalRef><RefSource>10.1016/j.hoc.2004.06.004</RefSource><RefTarget Address="10.1016/j.hoc.2004.06.004" TargetType="DOI"/></ExternalRef>.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_20">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Wilhelm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Carter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Lynch</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</ArticleTitle>
                <JournalTitle>Nat Rev Drug Discov</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>835</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>17016424</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrd2130</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVajsbbM</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_20">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Bruzek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>XW</Initials>
                  <FamilyName>Meng</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>6861</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16007148</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1208841</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFamsLbE</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_20">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Scripture</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Posadas</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A phase II clinical trial of sorafenib in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>209</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>18172272</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-1355</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXoslGm</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dahut WL, Scripture C, Posadas E, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008;14:209–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_20">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KN</Initials>
                  <FamilyName>Chi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Ellard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Hotte</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>746</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>18056648</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/annonc/mdm554</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD1c3gsVOgsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008;19:746–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_20">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Steinbild</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Mross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Frost</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>97</VolumeID>
                <FirstPage>1480</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>18040273</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.bjc.6604064</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtlKmt7vK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Steinbild S, Mross K, Frost A, et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007;97:1480–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_20">
              <CitationNumber>71</CitationNumber>
              <BibUnstructured>NCT00414388. Sorafenib to overcome resistance to systemic chemotherapy in androgen-independent prostate cancer. (Accessed September 22, 2007 at <ExternalRef>
                  <RefSource>http://clinicaltrials.gov/show/NCT00414388</RefSource>
                  <RefTarget Address="http://clinicaltrials.gov/show/NCT00414388" TargetType="URL"/>
                </ExternalRef>)</BibUnstructured>
            </Citation>
            <Citation ID="CR72_20">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LQ</Initials>
                  <FamilyName>Chow</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SG</Initials>
                  <FamilyName>Eckhardt</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Sunitinib: from rational design to clinical efficacy</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>884</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>17327610</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.06.3602</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjvVKmtLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_20">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Guerin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Formento</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Lo Nigro</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Cancer Res Clin Oncol</JournalTitle>
                <VolumeID>134</VolumeID>
                <FirstPage>51</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17593391</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00432-007-0247-4</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1KrurrF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Guerin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134:51–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_20">
              <CitationNumber>74</CitationNumber>
              <BibUnstructured>NCT00137436. Study of SU11248 in combination with docetaxel and prednisone in patients with prostate cancer. (Accessed September 22, 2007 at <ExternalRef>
                  <RefSource>http://clinicaltrials.gov/show/NCT00137436</RefSource>
                  <RefTarget Address="http://clinicaltrials.gov/show/NCT00137436" TargetType="URL"/>
                </ExternalRef>)</BibUnstructured>
            </Citation>
            <Citation ID="CR75_20">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Drevs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Siegert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Medinger</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>3045</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>17634482</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.07.2066</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXptlGrsbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_20">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Stadler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Roth</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>445</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>17458505</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s10637-007-9050-y</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXos1Cit7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007;25:445–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_20">
              <CitationNumber>77</CitationNumber>
              <BibUnstructured>Karakunnel JJ, Gulley J, Arlen P, et al. Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 2008;26:(May 20 suppl), No. 189.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_20">
              <CitationNumber>78</CitationNumber>
              <BibUnstructured>Mathew P, Pagliaro LC, Tannir NM, et al. Single-agent platelet-derived growth factor (PDGF) receptor inhibitor therapy for castration-resistant prostate cancer with bone metastases [abstract]. J Clin Oncol 2008:No.5164.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_20">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Janvier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sourla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Koutsilieris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Doillon</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>1551</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9179194</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2szit1Ojtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Janvier R, Sourla A, Koutsilieris M, Doillon C. Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Res 1997;17:1551–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_20">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Hepburn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Griffiths</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Harper</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Angiogenic factors expressed by human prostatic cell lines: effect on endothelial cell growth in vitro</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>33</VolumeID>
                <FirstPage>123</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>9316653</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(19971001)33:2&lt;123::AID-PROS6&gt;3.0.CO;2-L</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXms12hs78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hepburn PJ, Griffiths K, Harper ME. Angiogenic factors expressed by human prostatic cell lines: effect on endothelial cell growth in vitro. Prostate 1997;33:123–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_20">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>2532</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15226321</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.05.074</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWks7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_20">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>62</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11685731</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0093-7754(01)90157-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXotVemtr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001;28:62–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_20">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Franks</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Macpherson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Thalidomide</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>363</VolumeID>
                <FirstPage>1802</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>15172781</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(04)16308-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXksVanu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_20">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Tohnya</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SS</Initials>
                  <FamilyName>Ng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer</ArticleTitle>
                <JournalTitle>Clin Prostate Cancer</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>241</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>15072608</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2004.n.006</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXktlChtrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tohnya TM, Ng SS, Dahut WL, et al. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer 2004;2:241–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_20">
              <CitationNumber>85</CitationNumber>
              <BibUnstructured>Moss R, Mohile S, Shelton G, et al. A phase I open-label study using lenalidomide and docetaxel in androgen-independent prostate cancer (AIPC) [abstract]. In ASCO Prostate Cancer Symposium: Orlando, FL, February 22–24, 2007, No. 89.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_20">
              <CitationNumber>86</CitationNumber>
              <BibUnstructured>Sanborn SL, Cooney M, Gibbons J, et al. Phase I trial of daily lenalidomide and docetaxel given every three weeks in patients with advanced solid tumors. In ASCO Genitourinary Symposium: San Francisco, CA February 25–28, 2008, Abstract #183.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_20">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Rustin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Bradley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Galbraith</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">5, 6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>1160</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12698178</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.bjc.6600885</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXivFShs7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rustin GJ, Bradley C, Galbraith S, et al. 5,6- Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003;88:1160–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_20">
              <CitationNumber>88</CitationNumber>
              <BibUnstructured>Pili R, Rosenthal M, and AS1404-203 study group investigators<Emphasis Type="Italic">.</Emphasis> Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study. J Clin Oncol 2008;26(May 20 suppl), No. 5007.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_20">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Stupp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ruegg</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Integrin inhibitors reaching the clinic</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>1637</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17470853</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.09.8376</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlvFyktLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007;25:1637–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_20">
              <CitationNumber>90</CitationNumber>
              <BibUnstructured>Bradley DA, Daignault S, Ryan C, et al. Cilengitide in asymptomatic metastatic androgen independent prostate cancer (AIPC) patients (pts): A randomized phase II trial [abstract]. J Clin Oncol 2008;26(May 20 suppl), No. 5144.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_20">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Madigan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Kingsley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Cozzi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression</ArticleTitle>
                <JournalTitle>Cancer Immunol Immunother</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>1367</FirstPage>
                <LastPage>79</LastPage>
                <Occurrence Type="PID">
                  <Handle>18273614</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00262-008-0473-x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnsFeisL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Madigan MC, Kingsley EA, Cozzi PJ, et al. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 2008;57:1367–79.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_20">
              <CitationNumber>92</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>YM</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Jang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>5410</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>11034081</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXns1ehsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_20">
              <CitationNumber>93</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Logothetis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KK</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LD</Initials>
                  <FamilyName>Finn</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>1198</FirstPage>
                <LastPage>203</LastPage>
                <Occurrence Type="PID">
                  <Handle>11350884</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktlemu7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001;7:1198–203.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_20">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Lakhani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors</ArticleTitle>
                <JournalTitle>Cancer Biol Ther</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>22</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>16357512</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.4161/cbt.5.1.2349</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XkvVSntro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dahut WL, Lakhani NJ, Gulley JL, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006;5:22–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_20">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Hida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Hida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DN</Initials>
                  <FamilyName>Amin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Tumor-associated endothelial cells with cytogenetic abnormalities</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>8249</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>15548691</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-1567</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpvVGlurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004;64:8249–55.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
